NAFLD

A live -attenuated pneumococcal vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing the live -attenuated pneumococcal vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Live -attenuated pneumococcal vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down-regulation of its target gene, 12/September/2018, 11.58 pm
A live -attenuated pneumococcal vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing the live -attenuated pneumococcal vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Live -attenuated pneumococcal vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down-regulation of its target gene, 12/September/2018, 11.58 pm 960 720 Dr Boomi's Genom-2-Discovery Center

The significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people…

read more

Eating dark chocolate may lower cholesterol and triglyceride levels: Chocolate-based therapy for Non-alcoholic fatty liver disease (NAFLD): Monomeric cocoa catechins, found in dark chocolate, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down-regulation of its target gene, 3/September/2018, 12.15 am
Eating dark chocolate may lower cholesterol and triglyceride levels: Chocolate-based therapy for Non-alcoholic fatty liver disease (NAFLD): Monomeric cocoa catechins, found in dark chocolate, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down-regulation of its target gene, 3/September/2018, 12.15 am 960 720 Dr Boomi's Genom-2-Discovery Center

The significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people…

read more

Revealing the unrevealed function of  the reproductive hormone Relaxin in triglycerides/cholesterol reduction and in the treatment of Non-alcoholic fatty liver disease (NAFLD) : Relaxin, a protein hormone that facilitates labor and relaxes the uterine musculature,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of NAFLD, via down-regulation of its target gene, 19/August/2018, 11.45 pm
Revealing the unrevealed function of  the reproductive hormone Relaxin in triglycerides/cholesterol reduction and in the treatment of Non-alcoholic fatty liver disease (NAFLD) : Relaxin, a protein hormone that facilitates labor and relaxes the uterine musculature,  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of NAFLD, via down-regulation of its target gene, 19/August/2018, 11.45 pm 960 720 Dr Boomi's Genom-2-Discovery Center

The significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people…

read more

Vaccine for lowering cholesterol, and triglycerides levels: Repurposing the CTB-UE vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): CTB-UE vaccine, which protects against H.Pylori infection, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down regulation of its target gene, 1/August/2018, 3.16 pm
Vaccine for lowering cholesterol, and triglycerides levels: Repurposing the CTB-UE vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): CTB-UE vaccine, which protects against H.Pylori infection, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down regulation of its target gene, 1/August/2018, 3.16 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

A flu vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing Influenza A/flu(H1N1) vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Influenza A/flu(H1N1) vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via down regulation of its target gene, 12/July/2018, 1.04 pm
A flu vaccine-based therapy for lowering cholesterol, and triglycerides levels: Repurposing Influenza A/flu(H1N1) vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): Influenza A/flu(H1N1) vaccine decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via down regulation of its target gene, 12/July/2018, 1.04 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Cluster of differentiation (CD-30) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via down regulation of its target gene, 19/June/2018, 10.30
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Cluster of differentiation (CD-30) promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via down regulation of its target gene, 19/June/2018, 10.30 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more
Start Typing